Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Blood in your vomit (hematemesis) may be bright red, brown, or black. You may notice a small amount or have profuse bleeding. It could be caused by a range of health conditions in your upper ...

The results showed comparable efficacy between the two formulations, with objective response rates of 24.2% vs 18.2% for subcutaneous and intravenous nivolumab, respectively. Safety profiles were ...